A REAL-WORLD OBSERVATIONAL STUDY OF ETELCALCETIDE USE IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM IN EUROPE

被引：0
|
作者：
Louie, Karly [1 ]
Papadopoulou, Dorothea [2 ]
Hoffmann, Maxime [3 ]
Escola, Joaquin Manrique [4 ]
Kohnle, Matthias [5 ]
Cejka, Daniel [6 ]
Piccoli, Giorgina [7 ,8 ]
Rix, Marianne [9 ]
Boots, Johannes [10 ]
Pernat, Andreja Marn [11 ]
Torregrosa, Vicente [12 ]
Tsirtsonis, Kate [1 ]
Fouqueray, Bruno [13 ]
Floege, Juergen [14 ]
机构：
[1] Amgen Lth, Uxbridge, Middx, England
[2] Papageorgiou Hosp, Dept Nephrol, Thessaloniki, Greece
[3] Private Hosp La Louviere Ramsay Healthcare, Dept Nephrol & Dialysis, Lille, France
[4] Complejo Hosp Navarra, Nephrol Serv, Pamplona, Spain
[5] Nephrol Zentrum Mettmann, Mettmann, Germany
[6] Ordensklinikum Linz Elisabethinen, Dept Med 3, Nephrol, Transpantat Med,Rheumatol,Geriatr, Linz, Austria
[7] Ctr Hosp Le Mans, Le Mans, France
[8] Univ Torino, Turin, Italy
[9] Univ Hosp Copenhagen, Rigshosp, Dept Nephrol, Copenhagen, Denmark
[10] Maasstad Hosp, Dept Internal Med & Nephrol, Rotterdam, Netherlands
[11] Univ Med Ctr, Ljubljana, Slovenia
[12] Univ Barcelona, Hosp Clin, Nephrol & Renal Transplant Dept, Barcelona, Spain
[13] Amgen GmbH, Rotkreuz, Switzerland
[14] Rhein Westfal TH Aachen, Div Nephrol, Aachen, Germany
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2020年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
P0794
引用
收藏
页码：1122 / 1122
页数：1
相关论文
共 50 条
  • [31] Etelcalcetide controls secondary hyperparathyroidism and raises sclerostin levels in hemodialysis patients previously uncontrolled with cinacalcet
    Lopes Pereira, Luciano Artur
    Meng, Catarina
    Goncalves Amoedo, Manuel Augusto
    Pinto Ferreira Mendes, Maria Teresa de Sousa Costa
    Mateus Prazeres Marques, Marco Alexandre
    Machado Doria Frazao, Joao Miguel
    Loureiro Weigert, Andre Luiz
    NEFROLOGIA, 2023, 43 (02): : 197 - 203
  • [32] REAL-WORLD EFFECTIVENESS OF ETELCALCETIDE VS. CINACALCET IN US HEMODIALYSIS PATIENTS: A FACILITY CALCIMIMETIC PREFERENCE APPROACH
    Karaboyas, Angelo
    Muenz, Daniel
    Hwang, Yunji
    Goodman, William
    Cheng, Sunfa
    Desai, Pooja
    Fox, Kathleen
    Robinson, Bruce
    Pisoni, Ronald
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36
  • [33] A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism (the DUET Trial)
    Itano, Yuya
    Kato, Sawako
    Tsuboi, Masato
    Kasuga, Hirotake
    Tsuruta, Yoshinari
    Sato, Fumihiko
    Hishida, Manabu
    Ishimoto, Takuji
    Kosugi, Tomoki
    Ando, Masahiko
    Kuwatsuka, Yachiyo
    Maruyama, Shoichi
    KIDNEY INTERNATIONAL REPORTS, 2020, 5 (12): : 2168 - 2177
  • [34] Effect of switching from cinacalcet to etelcalcetide on secondary hyperparathyroidism in patients undergoing hemodialysis: an ESCORT trial
    Yuka Kurokawa
    Yusuke Kaida
    Takuma Hazama
    Yosuke Nakayama
    Takaomi Otome
    Ryo Shibata
    Sakuya Ito
    Goh Kodama
    Nao Nakamura
    Takatoshi Kambe
    Tomofumi Moriyama
    Akiko Nagata
    Aki Minami
    Ryotaro Ando
    Yoshifumi Wada
    Miki Sugiyama
    Michiaki Usui
    Michio Chiba
    Atsuo Moriyama
    Atsuko Ohara
    Hiroshi Miyazaki
    Tatsuyuki Kakuma
    Kei Fukami
    Renal Replacement Therapy, 6
  • [35] Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis
    Wu, Liviawati
    Melhem, Murad
    Subramanian, Raju
    Wu, Benjamin
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 (01) : 43 - 53
  • [36] Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism
    Takashi Shigematsu
    Masafumi Fukagawa
    Keitaro Yokoyama
    Takashi Akiba
    Akifumi Fujii
    Motoi Odani
    Tadao Akizawa
    Clinical and Experimental Nephrology, 2018, 22 : 426 - 436
  • [37] Etelcalcetide Versus Cinacalcet in Hemodialysis Patients in the United States: A Facility Calcimimetic Approach to Assess Real-World Effectiveness
    Karaboyas, Angelo
    Muenz, Daniel
    Hwang, Yunji
    Goodman, William
    Cheng, Sunfa
    Desai, Pooja
    Fox, Kathleen M.
    Robinson, Bruce M.
    Pisoni, Ronald L.
    KIDNEY MEDICINE, 2022, 4 (06)
  • [38] Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism
    Shigematsu, Takashi
    Fukagawa, Masafumi
    Yokoyama, Keitaro
    Akiba, Takashi
    Fujii, Akifumi
    Odani, Motoi
    Akizawa, Tadao
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2018, 22 (02) : 426 - 436
  • [39] Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis
    Liviawati Wu
    Murad Melhem
    Raju Subramanian
    Benjamin Wu
    Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44 : 43 - 53
  • [40] EARLIER: an observational study to evaluate the use of cinacalcet in incident hemodialysis patients with secondary hyperparathyroidism in daily clinical practice
    Hemetsberger, Margit
    Oberbauer, Rainer
    Erb, Helmut
    Pronai, Wolfgang
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2015, 165 (19-20) : 410 - 418
12345